MedTrace Logo

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

NCT05467748 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-01-27

No results posted yet for this study

Summary

This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Tulmimetostat

combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer

Sponsors & Collaborators

  • VA Greater Los Angeles Healthcare System

    collaborator FED

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Daniel S Shin, MD PhD · Michael E. DeBakey VA Medical Center, Houston, TX

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2027-12-08
Completion
2029-12-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05467748 on ClinicalTrials.gov